Previous 10 | Next 10 |
2024-02-09 07:48:15 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma Read the full article on Seeking Alpha For further details see: Evoke ...
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that i...
--News Direct-- Evoke Pharma CEO Dave Gonyer joined Steve Darling from Proactive to share news the company has achieved a significant milestone with the listing of its recently issued U.S. patent related to GIMOTI in the U.S. Food and Drug Administration's publication, commonly known as t...
SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that its recently...
SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that the United States Pat...
2023-11-10 08:55:21 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma For further details see: Evoke Pharma files to sell common stock and warrants
2023-11-09 09:00:42 ET More on Evoke Pharma Seeking Alpha’s Quant Rating on Evoke Pharma Historical earnings data for Evoke Pharma Financial information for Evoke Pharma For further details see: Evoke Pharma GAAP EPS of -$0.51, revenue of $1.56M
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide i...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Evoke Pharma Inc. (EVOK) is expected to report for Q1 2024
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK)...